罗克萨杜沙特通过调节HIF-2α/HIF-1α来改善CKD大鼠的血管化
Yujing Wang1, Min Xiao2, Feng Cai3
1Department of Hemodialysis, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
Environmental toxicology
|December 29, 2023
概括
在慢性病 (CKD) 的老鼠中,Roxadustat治疗通过调节低氧诱导因子2α (HIF-2α) 和HIF-1α,减少了血管化 (VC). 这项研究证明了roxadustatustat的存在.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
背景情况:
- 血管化 (VC) 是慢性病 (CKD) 的重要并发症,与骨质生分化有相似之处.
- 目前预防和治疗VC的策略仍然有限.
- 诱导缺氧的1α因子 (HIF-1α) 和内甲素-1 (ET-1) 已与VC发育有关.
研究的目的:
- 调查roxadustat在缓解CKD中的VC中的作用.
- 阐明roxadustat影响VC中的HIF-2α/HIF-1α通路的机制.
- 在VC的背景下探索HIF-1α和ET-1之间的相互作用.
主要方法:
- 基因测序用于识别化血管光滑肌细胞 (VSMC) 中的差异性基因表达.
- 同免疫沉 (CO-IP) 和酶试验证实了HIF-1α和ET-1之间的相互作用.
- 在体内研究中,使用使用roxadustat治疗的CKD大鼠模型,通过Alizarin红色染色,西部斑点和免疫组织化学评估.
- 在体外实验验验证roxadustat作用的HIF-2α/HIF-1α依赖性.
主要成果:
- 在CKD大鼠中,罗克萨杜沙特显著降低了血管和VSMC化.
- 在roxadustat治疗后,HIF-1α和ET-1的血清水平下降,而HIF-2α表达增加.
- 西部斑点分析证实HIF-1α和ET-1的表达减少,血管组织和化VSMC中的HIF-2α增加.
- 对HIF-1α激活或HIF-2α抑制的实验操纵逆转了roxadustat对VC的有益作用.
结论:
- 罗沙杜沙特有效地通过调节HIF-2α/HIF-1α信号通路来改善CKD中的血管化.
- 罗沙杜沙特对VC的治疗效果取决于HIF-2α和HIF-1α的调节.
- 这项研究提供了一种新的治疗策略,用于管理使用roxadustat. roxadustat. 的CKD患者的VC.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Antihypertensive Drugs: Vasodilators
528
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
528
Antihypertensive Drugs: Angiotensin II Receptor Blockers
735
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
735
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645


